Close Menu

Resolution Biosciences

LabCorp will be the exclusive provider of the test, which uses next-generation sequencing to look for actionable mutations cell-free DNA in NSCLC patients.

A study presented at the AACR meeting showed that Resolution's ctDx-Lung assay reported more oncogenic fusions than Guardant360 in NSCLC patients.

Investigators from the pharma concluded that most liquid biopsy false positives and negatives could be traced to technical specifics of individual tests.

The institutes will send patients samples to Resolution Bioscience, which will sequence circulating tumor DNA to identify the genetic causes of drug resistance.

The firm is moving into a larger facility after its first full year of profitability and planning new hires to support its plans to bring liquid biopsy kits through the FDA.

A circulating tumor DNA analysis identified somatic mutations in more than 64 percent of advanced non-small cell lung cancer cases, including some drug targets.

The company's ctDx lung cancer assay identifies a variety of different actionable mutations in the blood of non-small cell lung cancer patients.

Under the agreement, the Leidos-operated Frederick National Lab will evaluate Resolution's ctDx liquid biopsy sequencing platform.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.